Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
- Conditions
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Juan Du
- Target Recruit Count
- 90
- Registration Number
- NCT04941937
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Li Zheng
- Target Recruit Count
- 48
- Registration Number
- NCT04891744
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2020-12-22
- Target Recruit Count
- 62
- Registration Number
- NCT04680195
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04612582
- Locations
- 🇨🇳
Guangdong Provincial People'S Hospital, Guangzhou, Guangdong, China
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
- Conditions
- Interventions
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Emory University
- Target Recruit Count
- 17
- Registration Number
- NCT04352205
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2020-02-21
- Target Recruit Count
- 100
- Registration Number
- NCT04273529
The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2020-02-21
- Target Recruit Count
- 40
- Registration Number
- NCT04273581
CURATE.AI Optimized Modulation for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 20
- Registration Number
- NCT03759093
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Takeda
- Registration Number
- NCT03608501
- Locations
- 🇧🇷
Instituto COI de Educacao e Pesquisa, Rio de Janeiro, RJ, Brazil
🇧🇷Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
🇧🇷Universidade Estadual de Campinas UNICAMP - HEMOCENTRO, Campinas, SP, Brazil
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Yunpeng Liu
- Target Recruit Count
- 880
- Registration Number
- NCT03601871
- Locations
- 🇨🇳
Fushun Central Hospital, Fushun, Liaoning, China
🇨🇳cancer hospital of Haerbin Medical University, Haerbin, Heilongjiang, China
🇨🇳Siping City Cancer Hospital, Siping, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.